|Day Low/High||143.22 / 144.66|
|52 Wk Low/High||109.16 / 157.00|
Especially when healthcare CEOs discus political issues with analysts and reporters.
Recapping a big day of earnings for both names.
When Netflix reports earnings tonight, what will likely matter above all else for now will be subscriber growth.
The biggest challenge is even if JNJ beats and raises guidance, the overhang of litigation could still prevent overzealous trading.
Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.
There's been enough news with the lawsuits around this name to get the emotion back into the stock. Emotion often leads to volatility.
The best stocks to buy in this environment are the ones that have the greatest growth.
Wednesday was the first day that Netflix traded on above-average volume since Jan. 24.
Consider these five, right in front of you on this one day, so you get the perils of stock ownership and know how to handle them when they occur.
In this day and age, companies must be 'disruptors' or get left in the dust.
Did the Fed aid Microsoft? No, Microsoft aided Microsoft. J&J aided J&J. Procter aided Procter.
The approval of esketamine, known as Spravato, for use against severe depression is special -- it is saving lives.
Let's look at the charts and indicators to round out the picture.
I think this truly defines what has gone on with tech stocks since the latest reporting period began.
Eight of these 11 trade ideas are in the green, with a few big winners.
Dollar strength is affecting the competitive advantage of U.S. companies around the globe, and it is a more insidious problem that most people recognize.
These companies are working to plant their flag in a new landscape.
Is it a retest based on the damage the Fed has already done, the result of a breakdown in trade talks or a sign of a slowing global economy?
There's a lot of runway left to adjust guidance numbers moving forward.
Volatility appears to be the most attractive play during the early portion of earnings season.
While the ongoing litigation could be seen as a deterrent to investment, I think the more interesting story is its upcoming AFib detection study with Apple.
Experienced traders could approach the long side carefully.
It's centered around a few themed negatives, all forcing their own various uncertainties into free market price discovery.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
JNJ's current pennant pattern creates the potential for a big move in the month of January.
Shares have fallen hard, despite the company's vehement scientific and legal defense.